Phase 3 Alzheimer's Disease Trial, Recruiting NCT07323914 Sponsor: Xuanwu Hospital, Beijing Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 3 Alzheimer's Disease Trial, Recruiting

NCT07323914
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 50 and 90 years old at the time of joining.
  • People who have been diagnosed with probable Alzheimer's disease based on recognised diagnostic guidelines.
  • People whose Alzheimer's disease falls within a certain range of severity, from very mild to moderate, as measured by a standard assessment tool called the Clinical Dementia Rating scale (confirm with trial site).
  • People who have been diagnosed with ongoing (chronic) pain within the last 6 months, where a doctor has determined that opioid-based pain relief would be appropriate for them.
  • People whose pain has been confirmed and measured using a recognised pain assessment scale.
  • People who have had at least 4 to 6 years of formal schooling, or who are not illiterate.
  • People who are already taking medications for mood, behaviour, or memory, provided the doses have been stable for at least 3 months before joining and will remain unchanged during the study.
  • People who have a reliable carer or companion who can support them throughout the study and spend at least 8 hours per week with them.
  • People who are willing to take part in the trial, follow the assigned treatment plan throughout the study, and have signed a consent form.

Who may not be able to join:

  • People who have had a mini-stroke (TIA), stroke, or seizure in the past 12 months.
  • People who have a psychiatric diagnosis or symptoms — such as hallucinations, severe depression, or delusions — that might interfere with taking part in the study.
  • People who have a known allergy to opioid pain medicines.
  • People with severe problems with their vision or hearing.
  • People with alcohol dependence, substance abuse, or addiction to other drugs.
  • People who are currently taking part in another clinical trial for Alzheimer's disease treatment.
  • People who have another medical condition that is not well controlled or treated — for example, relating to the heart, lungs, digestive system, liver, or kidneys — or any condition the study doctor considers a safety concern.
  • People excluded for any other reason judged by the study doctor to make participation unsuitable.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yi Tang, M.D., Ph.D.

Phone: 00861083199456

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Xuanwu Hospital, Beijing
Registry
ClinicalTrials.gov
Start date
1 March 2025
Est. completion
1 January 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Pain Assessment in Advanced Dementia Scale (PAINAD)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov